Get the Stockscreener App
2.40
0.41%
-0.01
After Hours:
2.37
-0.03
-1.25%
Erasca Inc stock is traded at $2.40, with a volume of 1.12M.
It is down -0.41% in the last 24 hours and up +53.85% over the past month.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
See More
Previous Close:
$2.41
Open:
$2.42
24h Volume:
1.12M
Relative Volume:
0.83
Market Cap:
$680.81M
Revenue:
-
Net Income/Loss:
$-125.04M
P/E Ratio:
-2.9268
EPS:
-0.82
Net Cash Flow:
$-122.99M
1W Performance:
+3.00%
1M Performance:
+53.85%
6M Performance:
+93.55%
1Y Performance:
-12.73%
1-Day Range:
$2.36
$2.46
1-Week Range:
$2.21
$2.765
52-Week Range:
$1.01
$3.305
Erasca Inc Stock (ERAS) Company Profile
Name
Erasca Inc
Sector
Industry
Phone
(858) 465-6511
Address
3115 MERRYFIELD ROW, SAN DIEGO
Compare ERAS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ERAS
Erasca Inc
|
2.40 | 683.65M | 0 | -125.04M | -122.99M | -0.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Erasca Inc Stock (ERAS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-25 | Downgrade | BofA Securities | Buy → Underperform |
| Aug-18-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-26-25 | Initiated | Raymond James | Outperform |
| Nov-18-24 | Initiated | Jefferies | Buy |
| Mar-11-24 | Initiated | CapitalOne | Overweight |
| Jan-05-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-11-23 | Initiated | H.C. Wainwright | Buy |
| Mar-30-23 | Initiated | Mizuho | Buy |
| Feb-24-23 | Initiated | Goldman | Buy |
| Feb-03-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Erasca Inc Stock (ERAS) Latest News
Why Erasca Inc. stock remains a top recommendationInsider Selling & Verified Momentum Stock Alerts - newser.com
Heatmap analysis for Erasca Inc. and competitorsTrade Volume Summary & Reliable Price Breakout Alerts - newser.com
Is Erasca Inc. stock poised for growthJuly 2025 Intraday Action & Daily Stock Trend Reports - newser.com
What Fibonacci levels say about Erasca Inc. reboundIPO Watch & Advanced Swing Trade Entry Plans - newser.com
Best data tools to analyze Erasca Inc. stockTrade Analysis Summary & Free Fast Gain Swing Trade Alerts - newser.com
Custom watchlist performance reports with Erasca Inc.Earnings Overview Summary & AI Powered Buy/Sell Recommendations - newser.com
Discovering Potential: IZEA Worldwide And 2 Other Top Penny Stocks - simplywall.st
Is Erasca Inc. stock reversal real or fakeTrade Risk Assessment & High Win Rate Trade Alerts - newser.com
Statistical indicators supporting Erasca Inc.’s strength2025 Technical Patterns & Smart Investment Allocation Tips - newser.com
Is now a turning point for Erasca Inc.2025 Key Lessons & Free Verified High Yield Trade Plans - newser.com
Sector ETF performance correlation with Erasca Inc.July 2025 Pullbacks & Real-Time Chart Pattern Alerts - newser.com
What recovery options are there for Erasca Inc.Weekly Trading Summary & Long-Term Investment Growth Plans - newser.com
What institutional flow reveals about Erasca Inc.Quarterly Market Summary & Verified Chart Pattern Signals - newser.com
Published on: 2025-10-10 05:14:10 - newser.com
Short interest data insights for Erasca Inc.July 2025 Technicals & Smart Allocation Stock Tips - newser.com
Can Erasca Inc. rally from current levels2025 Macro Impact & Free Fast Entry Momentum Trade Alerts - newser.com
Will Erasca Inc. stock benefit from upcoming earnings reportsJuly 2025 Institutional & Stepwise Swing Trade Plans - newser.com
Why Erasca Inc. stock remains on buy lists2025 Short Interest & Long-Term Growth Portfolio Plans - newser.com
Erasca Target of Unusually High Options Trading (NASDAQ:ERAS) - Defense World
Erasca (NASDAQ:ERAS) Given Sell (D-) Rating at Weiss Ratings - Defense World
Unusually active option classes on open October 8th - TipRanks
Will Erasca Inc. price bounce be sustainableIndex Update & Accurate Entry/Exit Alerts - newser.com
Can swing trading help recover from Erasca Inc. losses2025 Price Momentum & Community Driven Trade Alerts - newser.com
Why retail investors favor Erasca Inc. stockMarket Performance Summary & Weekly High Conviction Ideas - newser.com
Erasca: Hype Building Into The End Of The Year (Rating Downgrade) (NASDAQ:ERAS) - Seeking Alpha
Fidus Investment, Rocket Companies And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Why Concorde International Group Shares Are Trading Higher By 55%; Here Are 20 Stocks Moving Premarket - Benzinga
Erasca Inc Stock (ERAS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):